• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过翻译后修饰对趋化因子活性的调控。

Regulation of chemokine activity by posttranslational modification.

作者信息

Mortier Anneleen, Van Damme Jo, Proost Paul

机构信息

Laboratory of Molecular Immunology, Rega Institute, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.

出版信息

Pharmacol Ther. 2008 Nov;120(2):197-217. doi: 10.1016/j.pharmthera.2008.08.006. Epub 2008 Aug 28.

DOI:10.1016/j.pharmthera.2008.08.006
PMID:18793669
Abstract

Chemokines regulate leukocyte migration during physiological and pathological conditions. They exert their biological activity through interaction with 7-transmembrane spanning G protein-coupled receptors (GPCR) and are presented on glycosaminoglycans (GAG) linked to endothelial cell layers. Specific chemokines and chemokine receptors affect angiogenesis or are targets for viral mimicry, e.g. by human immunodeficiency virus (HIV). Several enzymes, in particular proteases, have been described to process chemokines at specific sites generating chemokine isoforms that were also identified from natural sources. For some chemokines, e.g. CXCL8 and CCL3L1, posttranslational modification results in enhanced biological activity. For CXCL7 and CCL14 truncation is even mandatory for receptor signaling and chemotactic properties. The activity of many other chemokines is down-regulated by processing and receptor antagonists are generated, e.g. for truncated CCL8 and CCL11. Moreover, some processed chemokines such as CCL5(3-68) show enhanced affinity for one receptor (CCR5) and reduced interaction with other receptors (CCR1 and CCR3) resulting in differential changes in leukocyte response. These posttranslational mechanisms, in addition to gene duplication, transcriptional and translational regulation of chemokine ligand and receptor expression, GAG binding properties, expression of "silent" receptors and synergistic interaction between chemokines, modulate chemokine activity in a complex manner. This report reviews current understanding on the regulation of the chemokine network through posttranslational modification and its consequences for leukocyte migration, angiogenesis and protection against viral infection.

摘要

趋化因子在生理和病理条件下调节白细胞迁移。它们通过与7次跨膜的G蛋白偶联受体(GPCR)相互作用发挥生物学活性,并呈现在与内皮细胞层相连的糖胺聚糖(GAG)上。特定的趋化因子和趋化因子受体影响血管生成或成为病毒模拟的靶点,例如人类免疫缺陷病毒(HIV)。已描述了几种酶,特别是蛋白酶,可在特定位点加工趋化因子,产生也从天然来源鉴定出的趋化因子异构体。对于某些趋化因子,例如CXCL8和CCL3L1,翻译后修饰会导致生物学活性增强。对于CXCL7和CCL14,截断对于受体信号传导和趋化特性甚至是必需的。许多其他趋化因子的活性通过加工而被下调,并产生受体拮抗剂,例如针对截短的CCL8和CCL11。此外,一些加工后的趋化因子,如CCL5(3-68),对一种受体(CCR5)的亲和力增强,与其他受体(CCR1和CCR3)的相互作用减少,导致白细胞反应发生不同变化。这些翻译后机制,除了基因复制、趋化因子配体和受体表达的转录和翻译调控、GAG结合特性、“沉默”受体的表达以及趋化因子之间的协同相互作用外,还以复杂的方式调节趋化因子活性。本报告综述了目前对通过翻译后修饰调节趋化因子网络及其对白细胞迁移、血管生成和抗病毒感染保护作用的理解。

相似文献

1
Regulation of chemokine activity by posttranslational modification.通过翻译后修饰对趋化因子活性的调控。
Pharmacol Ther. 2008 Nov;120(2):197-217. doi: 10.1016/j.pharmthera.2008.08.006. Epub 2008 Aug 28.
2
CCR1- and CCR5-mediated inactivation of leukocytes by a nonglycosaminoglycan (non-GAG)-binding variant of n-nonanoyl-CCL14 (NNY-CCL14).非糖胺聚糖(非-GAG)结合型非壬酰化 CCL14(NNY-CCL14)对白细胞的 CCR1 和 CCR5 介导的失活作用。
J Leukoc Biol. 2010 Aug;88(2):383-92. doi: 10.1189/jlb.0509366. Epub 2010 May 18.
3
Overview of the mechanisms regulating chemokine activity and availability.概述调节趋化因子活性和可及性的机制。
Immunol Lett. 2012 Jul 30;145(1-2):2-9. doi: 10.1016/j.imlet.2012.04.015.
4
Effect of posttranslational processing on the in vitro and in vivo activity of chemokines.翻译后处理对趋化因子的体外和体内活性的影响。
Exp Cell Res. 2011 Mar 10;317(5):642-54. doi: 10.1016/j.yexcr.2010.11.016. Epub 2010 Dec 10.
5
The carboxyl terminus of the chemokine receptor CCR3 contains distinct domains which regulate chemotactic signaling and receptor down-regulation in a ligand-dependent manner.趋化因子受体CCR3的羧基末端包含不同的结构域,这些结构域以配体依赖的方式调节趋化信号传导和受体下调。
Eur J Immunol. 2005 Apr;35(4):1301-10. doi: 10.1002/eji.200425171.
6
Chemokine-protease interactions in cancer.癌症中的趋化因子-蛋白酶相互作用
Semin Cancer Biol. 2004 Jun;14(3):201-8. doi: 10.1016/j.semcancer.2003.10.007.
7
The allergy-associated chemokine receptors CCR3 and CCR5 can be inactivated by the modified chemokine NNY-CCL11.与过敏相关的趋化因子受体CCR3和CCR5可被修饰后的趋化因子NNY-CCL11灭活。
Allergy. 2007 Jan;62(1):17-24. doi: 10.1111/j.1398-9995.2006.01230.x.
8
Post-translational control of chemokines: a role for decoy receptors?趋化因子的翻译后调控:诱饵受体的作用?
Immunol Lett. 2005 Jan 31;96(2):163-74. doi: 10.1016/j.imlet.2004.08.018.
9
The chemokines, CX3CL1, CCL14, and CCL4, promote human trophoblast migration at the feto-maternal interface.趋化因子CX3CL1、CCL14和CCL4可促进人滋养层细胞在母胎界面处迁移。
Biol Reprod. 2006 May;74(5):896-904. doi: 10.1095/biolreprod.105.045518. Epub 2006 Feb 1.
10
Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13.人骨膜来源的祖细胞表达不同的趋化因子受体,并在CCL2、CCL25、CXCL8、CXCL12和CXCL13刺激下迁移。
Eur J Cell Biol. 2008 Jun;87(6):365-76. doi: 10.1016/j.ejcb.2008.03.009. Epub 2008 May 22.

引用本文的文献

1
The chemokine receptor CCR8 is not a high-affinity receptor for the human chemokine CCL18.趋化因子受体 CCR8 不是人源趋化因子 CCL18 的高亲和力受体。
PLoS One. 2024 Sep 11;19(9):e0305312. doi: 10.1371/journal.pone.0305312. eCollection 2024.
2
The Chemokine CXCL14 as a Potential Immunotherapeutic Agent for Cancer Therapy.趋化因子 CXCL14 作为癌症治疗的潜在免疫治疗药物。
Viruses. 2024 Feb 16;16(2):302. doi: 10.3390/v16020302.
3
CCL5's Role in Periodontal Disease: A Narrative Review.CCL5 在牙周病中的作用:一项叙述性综述。
Int J Mol Sci. 2023 Dec 11;24(24):17332. doi: 10.3390/ijms242417332.
4
Neutrophil-to-lymphocyte ratio as a promising non-invasive biomarker for symptom assessment and diagnosis of interstitial cystitis/bladder pain syndrome.中性粒细胞与淋巴细胞比值作为一种有前途的非侵入性生物标志物,可用于评估症状和诊断间质性膀胱炎/膀胱疼痛综合征。
BMC Urol. 2023 Nov 8;23(1):180. doi: 10.1186/s12894-023-01353-z.
5
Bioinformatic Analysis of the CXCR2 Ligands in Cancer Processes.癌症进程中 CXCR2 配体的生物信息学分析。
Int J Mol Sci. 2023 Aug 27;24(17):13287. doi: 10.3390/ijms241713287.
6
A review of the pleiotropic actions of the IFN-inducible CXC chemokine receptor 3 ligands in the synovial microenvironment.CXCR3 配体在滑膜微环境中的多效作用综述。
Cell Mol Life Sci. 2023 Mar 2;80(3):78. doi: 10.1007/s00018-023-04715-w.
7
The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.趋化因子 CXCL8 和 CXCL12:分子和功能特性、在疾病中的作用以及药理学干预的努力。
Cell Mol Immunol. 2023 Mar;20(3):217-251. doi: 10.1038/s41423-023-00974-6. Epub 2023 Feb 1.
8
ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.ADAM12 缺失可改变免疫细胞浸润,改善 T11 三阴性乳腺癌小鼠模型对检查点阻断治疗的反应。
Oncoimmunology. 2022 Dec 16;12(1):2158006. doi: 10.1080/2162402X.2022.2158006. eCollection 2023.
9
A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance.关于 LSD1 及其抑制剂在乳腺癌中的研究现状综述:分子机制与治疗意义
Front Pharmacol. 2022 Sep 16;13:989575. doi: 10.3389/fphar.2022.989575. eCollection 2022.
10
From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8.从 ELISA 到免疫吸附串联质谱法蛋白质组分析:以 CXCL8/白细胞介素-8 为例。
Front Immunol. 2021 Mar 11;12:644725. doi: 10.3389/fimmu.2021.644725. eCollection 2021.